Academic JournalOpen Access

JAMA Network Open

8 Papers Indexed in Blossom

Published Papers

Open Accessindividual

Negative Affect Circuit Subtypes and Neural, Behavioral, and Affective Responses to MDMA: A Randomized Clinical Trial

In a double‑blind, placebo‑controlled within‑participant randomised trial of 16 adults stratified by baseline nonconscious‑threat–evoked amygdala activity, 120 mg MDMA acutely reduced amygdala and subgenual ACC activity, increased sgACC–amygdala connectivity, and raised likability of threat expressions in the high‑reactivity subgroup (NTNA+) versus the low‑reactivity subgroup. These results indicate that baseline neuroimaging of negative affect circuitry can identify biomarkers to personalise MDMA‑based therapies.

Published
Journal
JAMA Network Open
Authors
Bertrand, C., Deisseroth, K., Gray, N. J., Hack, L. M., Heifets, B. D., Hilton, R., Knutson, B., Laudie, J., Rodriguez, C. I., Roessell, P. J. V., Suppes, T., Williams, L. M., Zhang, X.
Open Accessindividual

Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic

In a double‑blind randomised clinical trial of 30 US frontline clinicians with pandemic‑related depression, a single 25 mg psilocybin session (with preparatory and integration visits) produced a significantly greater reduction in clinician‑rated depressive symptoms at 28 days than 100 mg niacin (mean MADRS change −21.33 vs −9.33; mean difference −12.00, 95% CI −17.67 to −6.33; P < .001). Improvements in burnout and PTSD symptoms were numerically larger with psilocybin but did not reach statistical significance.

Published
Journal
JAMA Network Open
Authors
Back, A., Baker, K. K., Freeman-Young, T. K., Gooley, T. A., Harvey, K., Kaelen, M., Kelmendi, B., Kollefrath, A., McGregor, B., Morgan, L., Myers, S., Sethi, T., Sorta, D., Tai, M., Thomas, B. J.
Open Accessmeta

Developing an Ethics and Policy Framework for Psychedelic Clinical Care: A Consensus Statement

A multidisciplinary group produced a consensus ethics and policy framework for integrating government‑approved psychedelic medicines into clinical care, articulating 20 consensus points across five core ethical domains. The statement assigns responsible actors for implementation and identifies areas for further research and policy deliberation to promote equitable, safe adoption in mainstream medicine.

Published
Journal
JAMA Network Open
Authors
Baggott, M., Celidwen, Y., Cohen, I. G., Devenot, N., Gracias, S., Grob, C. S., Harvey, I., Kious, B., Marks, M., McGuire, A. L., Mithoefer, M. C., Nielson, E. M., Öngür, D., Pallas, A., Peterson, A., Schenberg, E. E., Sisti, D., Summergrad, P., Waters, B., Williams, M. T., Yaden, D. B.

Quick Facts

Papers Indexed
8
h-Index
154
Open Access
Yes
Publisher
American Medical Association
Country
United States
Website
Visit